GlycA

GlycA reflects several blood proteins involved in inflammation. Higher levels have been associated with heart attack, heart failure, certain cancers, severe infections, and earlier death. It often varies less than high-sensitivity C-reactive protein, or hs-CRP, but acute illness can raise it too. A single result can't distinguish temporary inflammation from a persistent problem.

This is an emerging marker with substantial human outcome data. Its role in guiding individual decisions is less established: there are no universally accepted treatment targets, and trials haven't shown that screening people with GlycA or treating to a particular level improves health outcomes. It can add information about inflammation, but its value depends on the question you're trying to answer.

What the Number Reflects

GlycA combines signals from sugar chains attached to several proteins, mainly alpha-1-acid glycoprotein, haptoglobin, alpha-1-antitrypsin, alpha-1-antichymotrypsin, and transferrin. These proteins are largely made in the liver. Inflammation changes their concentrations and the structure of their sugar chains, both of which can affect the result. They don't all respond in the same direction; transferrin generally falls during inflammation.

The sugar chains are attached through a controlled process inside cells. Hemoglobin A1c measures a different process: glucose attaching to hemoglobin without that cellular machinery. GlycA is therefore an inflammation marker, while HbA1c reflects blood sugar exposure over time.

The clinical assay uses serum or plasma separated from a venous blood sample. Nuclear magnetic resonance spectroscopy uses magnetic fields to detect chemical signals. Software separates the signal from particular chemical groups on the proteins' sugar chains from nearby signals and calculates GlycA in µmol/L. The number combines contributions from several proteins; it isn't the concentration of one molecule.

Several research platforms also report a measure called GlycA. Their signal definitions and calibration differ, so their absolute concentrations aren't interchangeable with the clinical assay. Research-platform findings below support associations with inflammation and disease, but they don't establish numerical targets for your result.

How Stable Is It?

In the original assay study, 23 healthy volunteers gave weekly samples over five weeks. Within-person variation was about 4.3% for GlycA and 29.2% for hs-CRP. That supports greater short-term stability under those study conditions, though these percentages aren't fixed properties of every person or population.

A study of young people using a research NMR platform found that GlycA tracked more consistently across roughly a decade than CRP did. The correlations between early and later measurements were 0.36 for GlycA and 0.07 for CRP. This was modest tracking, even for GlycA. Another longitudinal study found its advantage over hs-CRP depended on the interval between samples, with similar short-term stability in one comparison.

Risk of Earlier Death

Higher GlycA has been associated with mortality across several populations. A meta-analysis of seven studies involving about 63,000 people found about 74% higher relative mortality risk in the highest quarter than in the lowest quarter. This comparison describes groups followed in research; it doesn't translate directly into your chance of dying.

In the Dutch PREVEND study, about 5,500 adults were followed for an average of 12.6 years. Those in the highest quarter had about 43% higher mortality risk than those in the lowest quarter after adjustment for other risk factors and hs-CRP. In that analysis, hs-CRP no longer independently predicted death once GlycA was included.

Higher GlycA also predicted all-cause mortality in the Women's Health Study and the JUPITER trial. The Women's Health Study separately found associations with cardiovascular and cancer deaths. In the Multi-Ethnic Study of Atherosclerosis, or MESA, the mortality association persisted after accounting for hs-CRP and other inflammation and clotting markers.

A Finnish study using a different research NMR platform found a larger association among 900 people referred for imaging of their coronary arteries. Over 12 years, the two highest fifths each had roughly five times the mortality risk of the lowest fifth. That estimate came from a selected clinical population and shouldn't be applied to otherwise healthy adults.

Heart Attack and Artery Disease

GlycA and hs-CRP overlap, but their associations with cardiovascular outcomes aren't identical. Whether GlycA adds information after hs-CRP is included has varied across studies.

These findings support partly different information from the two markers. They don't establish that ordering both for everyone improves prevention decisions. GlycA also doesn't measure plaque directly.

In MESA, higher GlycA was associated with calcium buildup in parts of the thoracic aorta and around the mitral valve. Associations differed by location and weakened with adjustment for other risk factors. Smaller studies have also linked GlycA with plaque detected by vascular imaging.

Heart Failure

In MESA, about 6,500 adults were followed for a median of 14 years. Those in the highest quarter of GlycA had about 48% higher heart failure risk than those in the lowest quarter after adjustment for standard risk factors and hs-CRP.

The association was concentrated in heart failure with preserved ejection fraction, for which risk was roughly doubled. In this condition, the proportion of blood pumped out with each beat remains preserved, but the heart often fills poorly and develops high filling pressures. There was no clear association with heart failure with reduced ejection fraction. GlycA alone can't diagnose either form or tell which one you might develop.

Cancer and Serious Infection

Among four inflammation and clotting markers examined in MESA, GlycA was the only one independently associated with total cancer events. An analysis of the Women's Health Study and MESA also linked higher GlycA with colorectal cancer incidence and mortality. In PREVEND, the association with cancer mortality was found in men. These are observational associations, and GlycA hasn't been validated as a cancer screening test.

In Finnish cohorts using a research NMR platform, higher GlycA predicted later hospitalization or death from severe infections, including pneumonia and septicemia. It also tracked with gene activity related to neutrophils. These white blood cells respond to infection and tissue injury. The findings connect persistent immune activity with later infection risk, but an elevated result doesn't establish that you currently have an infection.

Body Fat, Blood Pressure, and Blood Sugar

In about 3,300 adolescents and young adults from the UK and Finland, a research-platform GlycA measurement was associated with later hypertension and metabolic syndrome over roughly a decade. Metabolic syndrome describes a cluster of abdominal obesity, raised blood pressure, abnormal blood fats, and impaired blood sugar regulation.

Genetic studies using inherited tendencies toward higher body mass index support excess body weight as a cause of higher GlycA. They don't establish which tissues or biological processes explain the entire effect.

In a small study of 58 adults with obesity, higher GlycA was associated with higher rates of fat breakdown and release after accounting for body fat. The corresponding hs-CRP associations didn't remain clear after that adjustment. This suggests that GlycA can reflect aspects of fat metabolism that aren't fully captured by body size.

In 50 young people with type 1 diabetes, higher GlycA was associated with more albumin leaking into urine and with measures of altered kidney circulation. These early findings don't establish GlycA as a substitute for urine albumin or standard kidney function tests.

Inflammatory Conditions and Gout

Studies in rheumatoid arthritis, inflammatory bowel disease, and psoriasis have linked GlycA with disease activity. In one rheumatoid arthritis study, it had moderate ability to distinguish low from moderate or high activity. In a small inflammatory bowel disease study using a different research NMR platform, GlycA was raised in some people whose CRP wasn't.

An exploratory study of early rheumatoid arthritis used another NMR glycoprotein method to add GlycA to a cardiovascular risk score. Among people with ultrasound-confirmed plaque, more were correctly classified as high risk once GlycA was added. That finding came from a small study and hasn't established a validated screening strategy for routine care.

In psoriasis, GlycA was associated with inflammation in artery walls and coronary disease beyond the information provided by hs-CRP. These associations make it a candidate additional marker, but they don't establish how a particular result should change treatment.

In about 105,000 UK Biobank participants measured on a research NMR platform, those in the highest fifth of GlycA had about 52% higher risk of developing gout than those in the lowest fifth, even after accounting for uric acid. The authors proposed that neutrophil-related inflammation could help explain the association. GlycA doesn't replace uric acid measurement or establish a gout diagnosis.

When a Low Number Isn't Reassuring

Advanced liver disease can complicate interpretation. In a study of people with cirrhosis awaiting transplantation, GlycA was lower than in population controls even though hs-CRP was higher. Impaired protein production and altered sugar-chain structure are possible explanations. Higher GlycA within the cirrhosis group was still associated with mortality, so the relationship wasn't a simple measure of how much liver function remained.

A low GlycA and high hs-CRP can occur for several reasons. That combination alone doesn't diagnose liver failure, and a low GlycA doesn't rule out an inflammatory disease.

When Results Can Be Misleading

• Acute illness or tissue injury: GlycA can rise during acute inflammation, including pancreatitis. A sample taken during illness may not represent your usual level.
• Advanced liver disease: changes in protein production and sugar-chain structure can weaken the usual relationship between GlycA and inflammation.
• Damage to red blood cells in the sample: hemolysis can lower the measured result. This is a sample-quality problem rather than evidence that inflammation improved.
• Different sample types or collection tubes: serum, EDTA plasma, and different tube types can produce systematic differences, even on the same assay.
• Different NMR platforms: signal definitions, calibration, and software differ. Results aren't necessarily interchangeable merely because both reports say GlycA or use the same unit.

Interpreting a Trend

Repeated measurements under comparable conditions can help show whether a change persists. A trend is easier to interpret alongside symptoms, disease activity, waist size, blood pressure, and metabolic results. Small fluctuations may still reflect ordinary variation or sample differences.

Your baseline provides context, but it isn't automatically a healthy target. A falling GlycA can accompany improvement in an underlying condition; the amount of decline needed to reduce future disease risk hasn't been established.